Comprehensive Cancer Centers of Nevada | Las Vegas, NV

Research site

(Unclaimed)

Location

3920 S Eastern Avenue, Suite 202, Las Vegas, Nevada, United States of America

Site insights

Top conditions

Top treatments

Pembrolizumab

Paclitaxel

Carboplatin

Docetaxel

Nivolumab

Cisplatin

Bevacizumab

Atezolizumab

Ipilimumab

Gemcitabine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

88 of 482 total trials

9-ING-41 in Patients with Advanced Cancers

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and e...

Active, not recruiting

Neoplasm of Lung

Neoplasms Pancreatic

Drug: Gemcitabine - 21 day cycle

Drug: 9-ING-41

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (CaDAnCe-101)

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation...

Enrolling

Waldenström Macroglobulinemia

Marginal Zone Lymphoma

Drug: BGB-16673

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

The primary objective of this study is:• To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia...

Invitation-only

Warm Antibody Autoimmune Hemolytic Anemia

Drug: Fostamatinib disodium

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA)

To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression...

Active, not recruiting

Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia

Drug: Rituximab

Drug: Venetoclax

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered...

Enrolling

Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

Drug: Gemcitabine

Drug: AMG 193

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling

Early Breast Cancer

Drug: Endocrine Therapy of Physician's Choice

Drug: Abemaciclib

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus tislelizumab when administered in combination with bevacizumab plus...

Active, not recruiting

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Drug: Capecitabine

Drug: Tislelizumab

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (pat...

Active, not recruiting

Colorectal Neoplasms

Drug: Ipilimumab

Drug: Atezolizumab

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer (CYCLONE 2)

This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants wi...

Active, not recruiting

Prostate Cancer

Drug: Placebo

Drug: Prednisone

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The prima...

Active, not recruiting

Melanoma

Biological: Pembrolizumab/Vibostolimab

Biological: Pembrolizumab

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (OrigAMI-2)

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chem...

Enrolling

Colorectal Neoplasms

Biological: Cetuximab

Biological: Amivantamab

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in particip...

Active, not recruiting

Non-small Cell Lung Cancer (NSCLC)

Drug: Tiragolumab

Drug: Durvalumab

A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SKYSCRAPER-02)

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and...

Active, not recruiting

Small Cell Lung Cancer

Drug: Etoposide

Drug: Tiragolumab

A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation (RAMP 201)

This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Lo...

Active, not recruiting

Low Grade Ovarian Serous Adenocarcinoma

Ovarian Cancer

Drug: avutometinib (VS-6766) and defactinib

Drug: avutometinib (VS-6766)

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in particip...

Active, not recruiting

Melanoma

Cancer

Biological: Ipilimumab

Other: Placebo

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It...

Enrolling

Urothelial Carcinoma

Drug: pembrolizumab

Drug: disitamab vedotin

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of...

Enrolling

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

Drug: Carboplatin

Drug: Pemetrexed

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order...

Active, not recruiting

Genes, Erbb-2

Receptors, Estrogen

Drug: Palbociclib (75, 100, 125 milligram [mg])

Drug: H3B-6545 (150, 300, 450 mg)

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed whil...

Active, not recruiting

Relapsed Cancer

Solid Tumor, Adult

Biological: Cemiplimab

Drug: HST-1011

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (BOLSTER)

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with previously untr...

Enrolling

Gallbladder Cancer

Bile Duct Cancer

Drug: Cisplatin

Drug: LSTA1